Ajanta Pharma Q4 Profit Rises 11% to ₹225 Crore

30 Apr 2025 , 04:50 PM

Ajanta Pharma has reported its Q4 numbers for fiscal year 2024–25. The company recorded a consolidated net profit of ₹225 crore in the March 2025 quarter. It is up by 11% from ₹203 crore in the same quarter the previous year. Revenue from operations also went up during the quarter. It climbed 11% year-on-year to ₹1,170 crore from ₹1,054 crore in Q4 FY24. The uptick reflects ongoing demand across Ajanta Pharma’s key business segments.

Ajanta Pharma’s Q4 FY25 EBITDA stood at ₹297 crore. This is a 7% increase from ₹278 crore in the year-earlier quarter. Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter. Over the entire fiscal, Ajanta Pharma achieved healthy returns to shareholders. It returned a total of ₹700 crore — ₹349 crore in dividends and ₹351 crore via share buyback. That amounts to a 76% payment of PAT for the year. The firm has a robust balance sheet yet.

Its chronic profitability and cautious use of capital exhibit a clear shareholder value mindset. Ajanta Pharma’s Q4 performance bears testament to its robustness against an industry of players. Strong local and international sales were adequate to support overall growth. The company remains committed to delivering enduring earnings and value to shareholders in the long run.